Compare DSY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSY | IFRX |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | China | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 86.0M |
| IPO Year | N/A | 2017 |
| Metric | DSY | IFRX |
|---|---|---|
| Price | $0.34 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 133.7K | ★ 904.9K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.37 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $7,323,356.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,075.42 |
| P/E Ratio | $28.81 | ★ N/A |
| Revenue Growth | ★ 16.37 | N/A |
| 52 Week Low | $0.32 | $0.71 |
| 52 Week High | $7.33 | $2.77 |
| Indicator | DSY | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 17.67 | 42.44 |
| Support Level | $0.32 | $1.00 |
| Resistance Level | $0.43 | $1.12 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 11.25 | 36.09 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.